CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
+0.53%Margins
Gross margin
94.9%
EBITDA margin
-280.6%
EBIT margin
-319.0%
Net margin
-289.4%
FCF margin
-243.7%
-41.0%
Return on equity
-28.2%
Return on assets
-36.7%
Return on invested capital
0.10x
Asset turnover
-$84.9M
Cash from operations
$2.06
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026